metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSO...
Journal Information
Vol. 29. Issue S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(February 2024)
Share
Share
Download PDF
More article options
Vol. 29. Issue S1.
Abstracts of the 2023 Annual Meeting of the ALEH
(February 2024)
Full text access
P-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY
Visits
121
Francisco Idalsoaga1, Luis Antonio Díaz1, Oscar Corsi1, Gustavo Ayares1, Jorge Arnold1, Winston Dunn2, Yanming Li2, Ashwani Singal3, Doug Simonetto4, María Ayala-Valverde5, Carolina A. Ramirez6, Dalia Morales-Arraez7, Wei Zhang8, Steve Qian8, Joseph Ahn4, Seth Buryska4, Heer Mehta2, Muhammad Waleed3, Horia Stefanescu9, Adelina Horhat9..., Andreea Bumbu9, Bashar Attar10, Rohit Agrawal11, Joaquín Cabezas12, Berta Cuyàs13, Maria Poca13, German Soriano Pastor13, Shiv K Sarin14, Rakhi Maiwall14, Prasun K Jalal15, María Fátima Higuera-De La Tijera16, Anand Kulkarni17, Nagaraja Rao17, Patricia Guerra Salazar18, Lubomir Skladaný19, Natália Bystrianska19, Veronica Prado20, Ana Clemente-Sanchez21, Diego Rincón21, Tehseen Haider22, Kristina R Chacko22, Gustavo A Romero23, Florencia D Pollarsky23, Juan Carlos Restrepo24, Luis G Toro25, Pamela Yaquich26, Manuel Mendizabal27, Maria Laura Garrido28, Sebastian Marciano29, Melisa Dirchwolf30, Victor Vargas31, Cesar Jimenez31, Guadalupe García-Tsao32, Guillermo Ortiz32, Juan G Abraldes33, Patrick Kamath4, Vijay Shah4, Ramon Bataller34, Juan Pablo Arab35Ver más
1 Departamento de Gastroenterología, Pontificia Universidad Católica de Chile, Santiago, Chile
2 University of Kansas Medical Center, KS, USA, Kansas, Estados Unidos (EEUU)
3 Division of Gastroenterology and Hepatology, Department of Medicine, University of South Dakota Sanford School of Medicine, Sioux Falls, SD, USA, Sioux Falls, Estados Unidos (EEUU)
4 Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA, Rochester, Estados Unidos (EEUU)
5 Hospital El Pino, Santiago, Chile
6 Department of Anesthesia, Schulich School of Medicine, Western University & London Health Sciences Centre, London, Ontario, Canada
7 Center for Liver Diseases, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, PA, USA, Pittsburgh, Estados Unidos (EEUU)
8 Division of Gastroenterology and Hepatology, University of Florida, Gainesville, FL, USA, Gainesville, Estados Unidos (EEUU)
9 Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania, Cluj-Napoca, Rumania
10 Division of Gastroenterology & Hepatology, Cook County Health and Hospital Systems, Chicago, Illinois, USA, Estados Unidos (EEUU)
11 Division of Gastroenterology and Hepatology, University of Illinois, Chicago, Illinois, Estados Unidos (EEUU)
12 Gastroenterology and Hepatology Department. Research Institute Valdecilla (IDIVAL). University Hospital Marques de Valdecilla. Santander. Spain
13 Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, CIBERehd, Barcelona, Spain
14 Institute of Liver and Biliary Sciences, New Delhi, India
15 Department of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, USA, Houston, Estados Unidos (EEUU)
16 Servicio de Gastroenterología, Hospital General de México, Universidad Nacional Autónoma de México, México DF, México
17 Asian Institute of Gastroenterology, Hyderabad, India
18 Instituto de Gastroenterología Boliviano-Japonés, La Paz, Bolivia
19 Division of Hepatology, Gastroenterology and Liver Transplantation, Department of Internal Medicine II, Slovak Medical University, F. D. Roosevelt University Hospital, Banska Bystrica, Slovak Republic
20 Centre Hospitalier de Luxembourg, Luxembourg
21 Liver Unit, Department of Digestive Diseases Hospital General Universitario Gregorio Marañón Madrid, Spain
22 Division of Gastroenterology and Hepatology, Montefiore Medical Center, Bronx, NY, USA, Estados Unidos (EEUU)
23 Sección Hepatología, Hospital de Gastroenterología Dr. Carlos Bonorino Udaondo, Buenos Aires, Argentina
24 Hospital Pablo Tobon Uribe, Universidad de Antioquia, Medellín, Colombia
25 Hospitales de San Vicente Fundación, Medellín-Rionegro, Antioquia, Colombia
26 Departamento de Gastroenterología, Hospital San Juan de Dios, Santiago, Chile
27 Hepatology and Liver Transplant Unit, Hospital Universitario Austral, Buenos Aires, Argentina
28 Hospital Central San Luis, San Luis, Argentina
29 Liver Unit, Hospital Italiano De Buenos Aires, Buenos Aires, Argentina
30 Unidad de Hígado, Hospital Privado de Rosario, Rosario, Argentina
31 Liver Unit, Hospital Vall d'Hebron, Universitat Autonoma Barcelona, CIBEREHD, Barcelona, Spain
32 Section of Digestive Diseases, Yale University School of Medicine/VA-CT Healthcare System, New Haven/West Haven, USA, New Haven/West Haven, Estados Unidos (EEUU)
33 Division of Gastroenterology, Liver Unit, University of Alberta, Edmonton, Canada
34 Liver Unit, Hospital Clinic, Barcelona, Spain
35 Division of Gastroenterology, Department of Medicine, Schulich School of Medicine, Western University & London Health Sciences Centre, London, Ontario, Canada
Ver más
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Figures (1)
Special issue
This article is part of special issue:
Vol. 29. Issue S1

Abstracts of the 2023 Annual Meeting of the ALEH

More info
Introduction and Objectives

Alcohol-associated hepatitis (AH) corresponds to a severe entity with high short-term mortality; however, few studies have been published in patients with moderate AH. This study aimed to characterize patients with moderate AH in a global study, identifying prognostic factors and survival at 30, 90, and 180 days.

Materials and Methods

Multi-center retrospective cohort study, which included patients with moderate AH (2009-2019). Moderate AH was defined as MELD 20 at presentation. We used competing-risk models with liver transplantation as a competing risk to assess variables associated with mortality.

Results

We included 564 patients (24 centers, 12 countries). Median age was 48±11.6 years, 29.2% female, and 46.2.5% Caucasian. 51.7% had cirrhosis, and 1.4% underwent liver transplantation. The MELD score on admission was 17 [6-20]. In the entire cohort, 37.7% used corticosteroids. Survival rates at 30, 90, and 180 days were 93.7% (0.911–0.955), 89.1% (0.860–0.916), and 87% (0.836–0.898), respectively. The most frequent causes of death were multiple organ failure (30.4%) and infections (11.5%). In the univariate analysis, variables associated with mortality were age (sHR 1.035, 95%CI:1.020–1.049; p <0.001), Maddrey's discriminant function (sHR 1.013, 95%CI:1.007–1.020; p<0.001), albumin at admission (sHR 0.837, 95%CI:0.682–1.026; p 0.087), INR (sHR 1.534; 95%CI: 1.070–2.198, p=0.020), renal replacement therapy (RRT) (sHR 7.066; 95%CI:4.381–11.392; p<0.001) and infections during hospitalization (sHR 2.079; 95%CI:1.308–3.306; p=0.002)(Table). However, in the multivariate-adjusted model, only age (sHR 1.042; 95%CI:1.019–1.0656, p<0.001), RRT (sHR 7.796; 95%CI:3.993–15.218, p<0.001) and infections during hospitalization (sHR 1.666; 95%CI:0.999–2.779; p=0.050) were associated with mortality. Of note, corticosteroids did not demonstrate benefit.

Conclusions

Patients with moderate AH have a significant mortality at short-term. Infections are associated with higher mortality and are the most important cause of death in these patients. Better models are necessary to predict mortality in moderate AH adequately.

Full text is only aviable in PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos